Home › Trials › NCT06659614
Clinical trial Recruiting at 1 site Observational Ages 18 and up Men only

Biobank for prostate tissue samples and genetic data

Official title: Prostate Tissue Biobank for People at Genetic Risk for Aggressive Disease

Run by Abramson Cancer Center at Penn Medicine · NCT06659614 · Data updated 2026-11-12

This study is collecting prostate tissue samples and DNA from men with inherited gene mutations to see how these genetic factors affect prostate cancer and treatment responses compared to men without these mutations.

Quick facts

Study typeObservational
Ages18 Years and up
SexMen only
Enrollment200 (estimated)
SponsorAbramson Cancer Center at Penn Medicine
Academic / other
Locations1 site (Philadelphia, Pennsylvania)
StatusRecruiting
StartedJanuary 1, 2024
Main results expectedJanuary 2034
Study endsJanuary 2034
Registry record updatedNovember 5, 2025
Trial IDNCT06659614 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include men with confirmed pathogenic variants in prostate cancer risk genes and those undergoing prostate biopsies or prostatectomies.

Probably not a fit

Patients without a genetic predisposition to prostate cancer or those not undergoing relevant procedures may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to create a biorepository of prostate tissue samples and matched germline DNA from men with inherited gene mutations linked to prostate cancer, as well as age-matched controls. It focuses on understanding the development of prostate cancer and treatment responses in carriers of specific genetic mutations compared to non-carriers. By collecting and analyzing these samples, researchers hope to gain insights into the genetic factors influencing prostate cancer outcomes.

Why it matters

Potential benefit: If successful, this study could enhance understanding of prostate cancer genetics and improve personalized treatment strategies for affected patients.

How similar studies have gone: Other studies have shown success in utilizing biobanks for genetic research in cancer, indicating a promising approach.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

Carriers (Group 1):

1. Confirmed pathogenic or likely pathogenic variant in a known prostate cancer risk gene.
2. Patients undergoing prostate biopsies as a part of their prostate cancer screening OR biopsy or prostatectomy due to a diagnosis of prostate cancer

Controls (Group 2):

1\. Patients undergoing prostate biopsies as a part of their prostate cancer screening OR biopsy or prostatectomy due to a diagnosis of prostate cancer

Exclusion Criteria:

* N/A

Where it's running

  • University of Pennsylvania
    Philadelphia, Pennsylvania, United States     Recruiting

Study contacts

  • Principal investigator: Kara N Maxwell, MD, PhD — University of Pennsylvania
  • Study coordinator: Kara N Maxwell, MD, PhD
  • Phone: 215-898-9698

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prostate Cancer 1464Genetic Predisposition 35Abramson Cancer Center at Penn Medicine 71
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.